Zhijia Wang

Zhijia Wang

Auto-generated profile, based on publicly available information

Zhijia Wang

Department of Biochemistry and Developmental Biology, University of Helsinki , Helsinki FIN-00014 , Finland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ZWZhijia Wang
Zhijia Wang
SHSamu V Himanen
Samu V Himanen
HHHeidi M Haikala
Heidi M Haikala
CFCaroline C Friedel
Caroline C Friedel
AVAnniina Vihervaara
Anniina Vihervaara
MBMatjaz Barboric
Matjaz Barboric
P-TEFb and CDK12 facilitate transcriptional elongation by RNA polymerase II. Given the prominence of both kinases in cancer, gaining a better understanding of their interplay could inform the design of novel anti-cancer strategies. While down-regulation of DNA repair genes in CDK12-targeted cancer cells is being explored therapeutically, little is known about mechanisms and significance of transcriptional induction upon inhibition of CDK12. We show that selective targeting of CDK12 in colon cancer-derived cells activates P-TEFb via its release from the inhibitory 7SK snRNP. In turn, P-TEFb stimulates Pol II pause release at thousands of genes, most of which become newly dependent on P-TEFb. Amongst the induced genes are those stimulated by hallmark pathways in cancer, including p53 and NF-κB. Consequently, CDK12-inhibited cancer cells exhibit hypersensitivity to inhibitors of P-TEFb. While blocking P-TEFb triggers their apoptosis in a p53-dependent manner, it impedes cell proliferation irrespective of p53 by preventing induction of genes downstream of the DNA damage-induced NF-κB signaling. In summary, stimulation of Pol II pause release at the signal-responsive genes underlies the functional dependence of CDK12-inhibited cancer cells on P-TEFb. Our study establishes the mechanistic underpinning for combinatorial targeting of CDK12 with either P-TEFb or the induced oncogenic pathways in cancer.

2 February 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
ZWZhijia Wang
Zhijia Wang
MMMonika Mačáková
Monika Mačáková
ABAndrii Bugai
Andrii Bugai
SKSergey G Kuznetsov
Sergey G Kuznetsov
AHAntti Hassinen
Antti Hassinen
MBMatjaz Barboric
Matjaz Barboric
Positive transcription elongation factor b (P-TEFb) is the crucial player in RNA polymerase II (Pol II) pause release that has emerged as a promising target in cancer. Because single-agent therapy may fail to deliver durable clinical response, targeting of P-TEFb shall benefit when deployed as a combination therapy. We screened a comprehensive oncology library and identified clinically relevant antimetabolites and Mouse double minute 2 homolog (MDM2) inhibitors as top compounds eliciting p53-dependent death of colorectal cancer cells in synergy with selective inhibitors of P-TEFb. While the targeting of P-TEFb augments apoptosis by anti-metabolite 5-fluorouracil, it switches the fate of cancer cells by the non-genotoxic MDM2 inhibitor Nutlin-3a from cell-cycle arrest to apoptosis. Mechanistically, the fate switching is enabled by the induction of p53-dependent pro-apoptotic genes and repression of P-TEFb-dependent pro-survival genes of the PI3K-AKT signaling cascade, which stimulates caspase 9 and intrinsic apoptosis pathway in BAX/BAK-dependent manner. Finally, combination treatments trigger apoptosis of cancer cell spheroids. Together, co-targeting of P-TEFb and suppressors of intrinsic apoptosis could become a viable strategy to eliminate cancer cells.

14 January 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
XMXu-Yang Mu
Xu-Yang Mu
ZWZhi-Jia Wang
Zhi-Jia Wang
BFBo Feng
Bo Feng
LXLei Xu
Lei Xu
LGLi-Xin Gao
Li-Xin Gao
WWWenlong Wang
Wenlong Wang
A series of 2-ethoxycarbonylthieno[2,3-b]quinolines were synthesized in the bio-derived “green” solvent γ-valerolactone and evaluated for their inhibitory activities against PTP1B, compound6adisplayed an IC50value of 8.04 ± 0.71 μM with 4.34-fold preference over TCPTP.

23 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ZWZhijia Wang
Zhijia Wang
SHSamu V. Himanen
Samu V. Himanen
HHHeidi M. Haikala
Heidi M. Haikala
CFCaroline C. Friedel
Caroline C. Friedel
AVAnniina Vihervaara
Anniina Vihervaara
MBMatjaz Barboric
Matjaz Barboric
P-TEFb and CDK12 facilitate transcriptional elongation by RNA polymerase II. Given the prominence of both kinases in cancer, gaining a better understanding of their interplay could inform the design of novel anti-cancer strategies. While down-regulation of DNA repair genes in CDK12-targeted cancer cells is being explored therapeutically, little is known about mechanisms and significance of transcriptional induction upon inhibition of CDK12. We show that selective targeting of CDK12 in colon cancer-derived cells activates P-TEFb via its release from the inhibitory 7SK snRNP. In turn, P-TEFb stimulates Pol II pause release at thousands of genes, most of which become newly dependent on P-TEFb. Amongst the induced genes are those stimulated by hallmark pathways in cancer, including p53 and NF-κB. Consequently, CDK12-inhibited cancer cells exhibit hypersensitivity to inhibitors of P-TEFb. While blocking P-TEFb triggers their apoptosis in a p53-dependent manner, it impedes cell proliferation irrespective of p53 by preventing induction of genes downstream of the DNA damage-induced NF-κB signaling. In summary, stimulation of Pol II pause release at the signal-responsive genes underlies the functional dependence of CDK12-inhibited cancer cells on P-TEFb. Our study establishes the mechanistic underpinning for combinatorial targeting of CDK12 with either P-TEFb or the induced oncogenic pathways in cancer.